Literature DB >> 21840395

Genetic modifiers of non-alcoholic fatty liver disease progression.

Quentin M Anstee1, Ann K Daly, Christopher P Day.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common cause of liver dysfunction worldwide. However, whilst the majority of individuals who exhibit features of the metabolic syndrome including obesity and insulin resistance will develop steatosis, only a minority progress to steatohepatitis, fibrosis and cirrhosis. Subtle inter-patient genetic variations and environment interact to determine disease phenotype and influence progression. A decade after the sequencing of the human genome, the comprehensive study of genomic variation offers new insights into the modifier genes, pathogenic mechanisms and is beginning to suggest novel therapeutic targets. We review the current status of the field with particular focus on advances from recent genome-wide association studies. 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21840395     DOI: 10.1016/j.bbadis.2011.07.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  24 in total

Review 1.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

2.  Genetic and hormonal control of hepatic steatosis in female and male mice.

Authors:  Frode Norheim; Simon T Hui; Emre Kulahcioglu; Margarete Mehrabian; Rita M Cantor; Calvin Pan; Brian W Parks; Aldons J Lusis
Journal:  J Lipid Res       Date:  2016-11-03       Impact factor: 5.922

Review 3.  Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Authors:  Helen L Reeves; Marco Y W Zaki; Christopher P Day
Journal:  Dig Dis Sci       Date:  2016-02-26       Impact factor: 3.199

4.  TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD.

Authors:  Giovanni Musso; Ugo Cipolla; Maurizio Cassader; Silvia Pinach; Francesca Saba; Franco De Michieli; Elena Paschetta; Daria Bongiovanni; Luciana Framarin; Nicola Leone; Mara Berrutti; Floriano Rosina; Stefania Corvisieri; Federica Molinaro; Antonio Sircana; Roberto Gambino
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

5.  NAFLD Susceptibility Genes and their Association with Type 2 Diabetes and Obesity in a New Mexico Population.

Authors:  Cara J Garner; Carole A Conn; Deborah Cohen; Li Luo; Joseph J Castillo; Vallabh O Shah; William S Garver
Journal:  J Diabetes Obes       Date:  2015-07-27

6.  Loss of L-FABP, SCP-2/SCP-x, or both induces hepatic lipid accumulation in female mice.

Authors:  Gregory G Martin; Barbara P Atshaves; Kerstin K Landrock; Danilo Landrock; Friedhelm Schroeder; Ann B Kier
Journal:  Arch Biochem Biophys       Date:  2015-06-24       Impact factor: 4.013

7.  Nonalcoholic Fatty Liver Disease Is a Susceptibility Factor for Perchloroethylene-Induced Liver Effects in Mice.

Authors:  Joseph A Cichocki; Shinji Furuya; Yu-Syuan Luo; Yasuhiro Iwata; Kranti Konganti; Weihsueh A Chiu; David W Threadgill; Igor P Pogribny; Ivan Rusyn
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

8.  Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.

Authors:  Rhiannon N Hardwick; John D Clarke; April D Lake; Mark J Canet; Tarun Anumol; Stephanie M Street; Matthew D Merrell; Michael J Goedken; Shane A Snyder; Nathan J Cherrington
Journal:  Toxicol Sci       Date:  2014-07-31       Impact factor: 4.849

Review 9.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Authors:  Quentin M Anstee; Giovanni Targher; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-19       Impact factor: 46.802

Review 10.  Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias.

Authors:  Friedhelm Schroeder; Avery L McIntosh; Gregory G Martin; Huan Huang; Danilo Landrock; Sarah Chung; Kerstin K Landrock; Lawrence J Dangott; Shengrong Li; Martin Kaczocha; Eric J Murphy; Barbara P Atshaves; Ann B Kier
Journal:  Lipids       Date:  2016-04-27       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.